There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Castle Biosciences Inc. (CSTL) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.54, or -1.98%, to $26.67. The Castle Biosciences Inc. has recorded 2,775 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results.
This NASDAQ-listed company operates within the Diagnostics & Research industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $27.21 and fluctuated between $27.37 as its day high and $25.85 as its day low. The current market capitalization of Castle Biosciences Inc. is $685.96M. A total of 0.13 million shares were traded on the day, compared to an average of 201.66K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, CSTL has seen 12 BUY and 67 SELL insider trades, representing the acquisition of 59,659 and the disposition of 64,225 shares. Over the last 12 months, there were 26 BUYs and 290 SELLs from insiders. Insiders purchased 162,523 shares during that period but sold 267,366.
In the most recent transaction, BRADBURY DANIEL sold 7,704 shares of CSTL for 22.89 per share on Jan 03. After the transaction, the Director now owns 199,539 company shares. In a previous transaction on Jan 03, MAETZOLD DEREK J sold 5,125 shares at 22.90 per share. CSTL shares that Pres. & Chief Exec. Officer owns now total 25,093.
Among the insiders who sold shares, MAETZOLD DEREK J disposed of 3,833 shares on Jan 03 at a per-share price of $22.90. This resulted in the Pres. & Chief Exec. Officer holding 301,529 shares of CSTL after the transaction. In another insider transaction, MAETZOLD DEREK J sold 5,125 shares at $23.07 per share on Dec 19. Company shares held by the Pres. & Chief Exec. Officer now total 25,468.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CSTL in the last 3 months, the mean price target is $49.50 with high estimates of $63.00 and low estimates of $40.00. In terms of 52-week highs and lows, CSTL has a high of $48.40 and a low of $15.58.
As of this writing, CSTL has an earnings estimate of -$0.88 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.41 per share and a lower estimate of -$1.06. The company reported an EPS of -$0.97 in the last quarter, which was -36.60% lower than expectations of -$0.71.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CSTL is Overweight with a score of 5.00. A total of 7 analysts rated the stock as Buy while 1 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.